<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Praxis Precision Medicines Inc — News on 6ix</title>
    <link>https://6ix.com/company/praxis-precision-medicines-inc</link>
    <description>Latest news and press releases for Praxis Precision Medicines Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 14 Apr 2026 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/praxis-precision-medicines-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835b00978dffbe2df10f7fa.webp</url>
      <title>Praxis Precision Medicines Inc</title>
      <link>https://6ix.com/company/praxis-precision-medicines-inc</link>
    </image>
    <item>
      <title>Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor</title>
      <link>https://6ix.com/company/praxis-precision-medicines-inc/news/praxis-precision-medicines-announces-fda-acceptance-of-new-drug-application-for-ulixacaltamide-hcl-in-patients-with-essential-tremor</link>
      <guid isPermaLink="true">https://6ix.com/company/praxis-precision-medicines-inc/news/praxis-precision-medicines-announces-fda-acceptance-of-new-drug-application-for-ulixacaltamide-hcl-in-patients-with-essential-tremor</guid>
      <pubDate>Tue, 14 Apr 2026 04:00:00 GMT</pubDate>
      <description>FDA assigned PDUFA target action date of January 29, 2027 No advisory committee meeting expected BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Praxis Precision</description>
    </item>
    <item>
      <title>Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy</title>
      <link>https://6ix.com/company/praxis-precision-medicines-inc/news/praxis-precision-medicines-announces-positive-results-from-the-embrave-part-a-trial-of-elsunersen-in-patients-with-scn2a-early-onset-developmental-and-epileptic-encephalopathy</link>
      <guid isPermaLink="true">https://6ix.com/company/praxis-precision-medicines-inc/news/praxis-precision-medicines-announces-positive-results-from-the-embrave-part-a-trial-of-elsunersen-in-patients-with-scn2a-early-onset-developmental-and-epileptic-encephalopathy</guid>
      <pubDate>Mon, 06 Apr 2026 04:00:00 GMT</pubDate>
      <description>Elsunersen demonstrated placebo-adjusted seizure reduction from baseline of 77% (p=0.015) 71% of elsunersen-treated patients achieved &gt;50% seizure reduction</description>
    </item>
    <item>
      <title>Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs</title>
      <link>https://6ix.com/company/praxis-precision-medicines-inc/news/praxis-precision-medicines-announces-fda-acceptance-and-priority-review-of-new-drug-application-for-relutrigine-in-patients-with-scn2a-and-scn8a-dees</link>
      <guid isPermaLink="true">https://6ix.com/company/praxis-precision-medicines-inc/news/praxis-precision-medicines-announces-fda-acceptance-and-priority-review-of-new-drug-application-for-relutrigine-in-patients-with-scn2a-and-scn8a-dees</guid>
      <pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
      <description>FDA assigned PDUFA target action date of September 27, 2026 BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a</description>
    </item>
    <item>
      <title>Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results</title>
      <link>https://6ix.com/company/praxis-precision-medicines-inc/news/praxis-precision-medicines-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2025-financial-results</link>
      <guid isPermaLink="true">https://6ix.com/company/praxis-precision-medicines-inc/news/praxis-precision-medicines-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
      <pubDate>Thu, 19 Feb 2026 12:30:00 GMT</pubDate>
      <description>Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) have been submitted to the U.S. Food and Drug Administration (FDA) Pre-launch activities for ulixacaltamide and relutrigine are underway and will accelerate through 2026 Essential3 results to be presented as an oral presentation at the American Academy of Neurology Annual Meeting Cash and investments of $926 million as of December</description>
    </item>
    <item>
      <title>Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences</title>
      <link>https://6ix.com/company/praxis-precision-medicines-inc/news/praxis-precision-medicines-report-fourth-210100847</link>
      <guid isPermaLink="true">https://6ix.com/company/praxis-precision-medicines-inc/news/praxis-precision-medicines-report-fourth-210100847</guid>
      <pubDate>Mon, 09 Feb 2026 21:01:00 GMT</pubDate>
      <description>BOSTON, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will report its financial results for the fourth quarter and full year ended December 31, 2025, and provide a corporate update before the financial markets open on Thursday, February 19, 2026. The Company will host a conference call and a live webcast to review the fourth quarter fi</description>
    </item>
    <item>
      <title>SEQSTER Announces Expanded Partnership with Praxis Precision Medicines to Accelerate Clinical Trials in CNS Disorders</title>
      <link>https://6ix.com/company/praxis-precision-medicines-inc/news/seqster-announces-expanded-partnership-with-praxis-precision-medicines-to-accelerate-clinical-trials-in-cns-disorders</link>
      <guid isPermaLink="true">https://6ix.com/company/praxis-precision-medicines-inc/news/seqster-announces-expanded-partnership-with-praxis-precision-medicines-to-accelerate-clinical-trials-in-cns-disorders</guid>
      <pubDate>Mon, 02 Feb 2026 14:57:00 GMT</pubDate>
      <description>SAN DIEGO &amp; BOSTON, February 02, 2026--SEQSTER, the leading healthcare technology company and the data connection, collection, and orchestration layer for patient health data, and Praxis Precision Medicines, Inc., today announced the expansion of a successful partnership to accelerate clinical trials, data collection, and real-world evidence (RWE) generation across Praxis&apos;s clinical development programs.</description>
    </item>
    <item>
      <title>Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy</title>
      <link>https://6ix.com/company/praxis-precision-medicines-inc/news/praxis-precision-medicines-appoints-global-213000194</link>
      <guid isPermaLink="true">https://6ix.com/company/praxis-precision-medicines-inc/news/praxis-precision-medicines-appoints-global-213000194</guid>
      <pubDate>Tue, 13 Jan 2026 21:30:00 GMT</pubDate>
      <description>BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced the appointment of world-renowned neurologist and epilepsy authority Dr. Orrin Devinsky, M.D., as Head of Clinical Strategy, a newly created leadership role. Dr. Devinsky is widely regarded as one of the most influential physician-scientists of his generation in modern epilepsy and cli</description>
    </item>
    <item>
      <title>Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress</title>
      <link>https://6ix.com/company/praxis-precision-medicines-inc/news/praxis-precision-medicines-enters-its-next-chapter-following-pivotal-year-progress</link>
      <guid isPermaLink="true">https://6ix.com/company/praxis-precision-medicines-inc/news/praxis-precision-medicines-enters-its-next-chapter-following-pivotal-year-progress</guid>
      <pubDate>Mon, 12 Jan 2026 05:00:00 GMT</pubDate>
      <description>Two NDA submissions expected by mid-February 2026 for ulixacaltamide in essential tremor and relutrigine in SCN2A/8A-DEEs, both with Breakthrough Therapy</description>
    </item>
    <item>
      <title>Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
      <link>https://6ix.com/company/praxis-precision-medicines-inc/news/praxis-precision-medicines-inc-announces-210100049</link>
      <guid isPermaLink="true">https://6ix.com/company/praxis-precision-medicines-inc/news/praxis-precision-medicines-inc-announces-210100049</guid>
      <pubDate>Fri, 09 Jan 2026 21:01:00 GMT</pubDate>
      <description>BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on January 2, 2026, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 434 shares of its common stock to three n</description>
    </item>
    <item>
      <title>Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments</title>
      <link>https://6ix.com/company/praxis-precision-medicines-inc/news/praxis-precision-medicines-further-positioned-214500067</link>
      <guid isPermaLink="true">https://6ix.com/company/praxis-precision-medicines-inc/news/praxis-precision-medicines-further-positioned-214500067</guid>
      <pubDate>Thu, 08 Jan 2026 21:45:00 GMT</pubDate>
      <description>BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation–inhibition imbalance, today announced the appointment of Jeffrey B. Kindler and Stuart Arbuckle to its board of directors, and the promotions of Megan Sniecinski to Chief Operating Officer and Dr. Steven Petrou to President</description>
    </item>
    <item>
      <title>Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering</title>
      <link>https://6ix.com/company/praxis-precision-medicines-inc/news/praxis-precision-medicines-inc-announces-041500032</link>
      <guid isPermaLink="true">https://6ix.com/company/praxis-precision-medicines-inc/news/praxis-precision-medicines-inc-announces-041500032</guid>
      <pubDate>Wed, 07 Jan 2026 04:15:00 GMT</pubDate>
      <description>BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the pricing of its underwritten public offering of 2,212,000 shares of its common stock at a public offering price per share of $260.00. The gross proceeds from the offering are expecte</description>
    </item>
    <item>
      <title>Praxis Precision Medicines, Inc. Announces Proposed Public Offering</title>
      <link>https://6ix.com/company/praxis-precision-medicines-inc/news/praxis-precision-medicines-inc-announces-proposed-public-offering-2026-01-06</link>
      <guid isPermaLink="true">https://6ix.com/company/praxis-precision-medicines-inc/news/praxis-precision-medicines-inc-announces-proposed-public-offering-2026-01-06</guid>
      <pubDate>Tue, 06 Jan 2026 05:00:00 GMT</pubDate>
      <description>BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic</description>
    </item>
    <item>
      <title>Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor</title>
      <link>https://6ix.com/company/praxis-precision-medicines-inc/news/praxis-precision-medicines-announces-fda-has-granted-breakthrough-therapy-designation</link>
      <guid isPermaLink="true">https://6ix.com/company/praxis-precision-medicines-inc/news/praxis-precision-medicines-announces-fda-has-granted-breakthrough-therapy-designation</guid>
      <pubDate>Mon, 29 Dec 2025 05:00:00 GMT</pubDate>
      <description>The Breakthrough Therapy Designation was granted based on the positive topline results from the Essential3 Phase 3 program in essential tremor Praxis remains</description>
    </item>
    <item>
      <title>Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026</title>
      <link>https://6ix.com/company/praxis-precision-medicines-inc/news/praxis-precision-medicines-announces-plans-file-nda-relutrigine-scn2a-and-scn8a</link>
      <guid isPermaLink="true">https://6ix.com/company/praxis-precision-medicines-inc/news/praxis-precision-medicines-announces-plans-file-nda-relutrigine-scn2a-and-scn8a</guid>
      <pubDate>Thu, 11 Dec 2025 05:00:00 GMT</pubDate>
      <description>EMBOLD data to serve as basis of efficacy and safety following discussion with the FDA BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines,</description>
    </item>
    <item>
      <title>Praxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic Encephalopathy</title>
      <link>https://6ix.com/company/praxis-precision-medicines-inc/news/praxis-precision-medicines-announces-alignment-fda-simplified-and-accelerated</link>
      <guid isPermaLink="true">https://6ix.com/company/praxis-precision-medicines-inc/news/praxis-precision-medicines-announces-alignment-fda-simplified-and-accelerated</guid>
      <pubDate>Tue, 09 Dec 2025 05:00:00 GMT</pubDate>
      <description>Clear recognition of high unmet need and urgency for the SCN2A community and plausibility of the mechanism of elsunersen FDA agreed to proposed changes to the</description>
    </item>
    <item>
      <title>Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies</title>
      <link>https://6ix.com/company/praxis-precision-medicines-inc/news/praxis-aes-wrap-best-class-potential-across-rare-pediatric-and-adult-epilepsies-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/praxis-precision-medicines-inc/news/praxis-aes-wrap-best-class-potential-across-rare-pediatric-and-adult-epilepsies-2025</guid>
      <pubDate>Mon, 08 Dec 2025 05:00:00 GMT</pubDate>
      <description>Positive Results in the EMBOLD study of relutrigine showed a 53% placebo-adjusted reduction in seizures (p Patients in the RADIANT study of vormatrigine</description>
    </item>
    <item>
      <title>Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies</title>
      <link>https://6ix.com/company/praxis-precision-medicines-inc/news/praxis-precision-medicines-announces-positive-results-embold-study-relutrigine-scn2a</link>
      <guid isPermaLink="true">https://6ix.com/company/praxis-precision-medicines-inc/news/praxis-precision-medicines-announces-positive-results-embold-study-relutrigine-scn2a</guid>
      <pubDate>Thu, 04 Dec 2025 05:00:00 GMT</pubDate>
      <description>Successful interim analysis triggered early stop for efficacy Topline study results to be shared at the American Epilepsy Society Annual Meeting on December</description>
    </item>
    <item>
      <title>Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor</title>
      <link>https://6ix.com/company/praxis-precision-medicines-inc/news/praxis-precision-medicines-announces-positive-pre-nda-meeting-fda-ulixacaltamide</link>
      <guid isPermaLink="true">https://6ix.com/company/praxis-precision-medicines-inc/news/praxis-precision-medicines-announces-positive-pre-nda-meeting-fda-ulixacaltamide</guid>
      <pubDate>Thu, 04 Dec 2025 05:00:00 GMT</pubDate>
      <description>Praxis confirms plans to submit the essential tremor NDA for ulixacaltamide in early 2026 BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision</description>
    </item>
    <item>
      <title>Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting</title>
      <link>https://6ix.com/company/praxis-precision-medicines-inc/news/praxis-present-latest-preclinical-and-clinical-advancements-across-leading-epilepsy</link>
      <guid isPermaLink="true">https://6ix.com/company/praxis-precision-medicines-inc/news/praxis-present-latest-preclinical-and-clinical-advancements-across-leading-epilepsy</guid>
      <pubDate>Mon, 24 Nov 2025 05:00:00 GMT</pubDate>
      <description>BOSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic</description>
    </item>
    <item>
      <title>Praxis Precision Medicines to Participate in Upcoming Fireside Chat</title>
      <link>https://6ix.com/company/praxis-precision-medicines-inc/news/praxis-precision-medicines-participate-upcoming-fireside-chat-2025-11-20</link>
      <guid isPermaLink="true">https://6ix.com/company/praxis-precision-medicines-inc/news/praxis-precision-medicines-participate-upcoming-fireside-chat-2025-11-20</guid>
      <pubDate>Thu, 20 Nov 2025 05:00:00 GMT</pubDate>
      <description>BOSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic</description>
    </item>
  </channel>
</rss>